Why FormFactor (FORM) Might be Well Poised for a Surge

FormFactor’s consensus EPS estimates are moving higher, with the current-quarter estimate at $0.61 per share, up 125.9% year over year and 12.78% over the last 30 days. Full-year EPS is now expected at $2.40, up 84.6% year over year and 7.14% in the past month, helping the stock earn a Zacks Rank #1 (Strong Buy). The article argues the positive revision trend and a 10.3% four-week share gain could support further upside.

Analysis

FORM is increasingly looking like a classic estimate-revision momentum trade, but the important second-order effect is that improving sell-side confidence can matter more here than near-term fundamentals. In semi-cap equipment names, multiple expansion often starts before revenue inflects because investors price in a cleaner forward booking cycle; if revisions keep trending up, the stock can keep re-rating even without a major new catalyst. That makes this less about one quarter and more about whether the market believes the downcycle has already bottomed.

The main beneficiaries are likely to be other testing/inspection and wafer-level metrology names, because a visible upgrade cycle in one diagnostic supplier usually implies customers are normalizing capex across the broader process-control stack. The flip side is that if FORM is leading the tape on revisions, underappreciated peers with weaker estimate momentum may lag despite similar end-market exposure. That creates an attractive relative-value setup rather than a pure directionally bullish one.

The key risk is that estimate revisions are a lagging indicator if the upside is driven by a temporary order push rather than a sustained recovery in wafer-fab equipment spending. Over the next 1-3 months, the stock can continue to work higher on momentum alone, but over 6-12 months the tape will care more about whether guidance confirms actual demand durability and margin leverage. Any slowdown in revision cadence, even without a miss, could compress the multiple quickly because the stock is already trading with improving sentiment embedded.

Consensus may be underestimating how far this can run if systematic and quant flows are still early in the re-rating process. But the move also looks somewhat crowded in the sense that the market is explicitly buying the revision story, so upside likely depends on continued estimate upgrades rather than just a stable quarter. That argues for participation with defined downside rather than an outright unhedged chase.

Key Decisions for Investors

• Go long FORM for 1-3 months into the next revision cycle; use a stop if consensus stops rising, because the trade is momentum-dependent rather than valuation-dependent.
• Pair trade: long FORM / short a slower-moving semiconductor equipment or inspection peer with weaker estimate momentum over the next 4-8 weeks; this isolates revision leadership and reduces index beta.
• For tactical upside, buy near-dated call spreads on FORM into the next earnings window; the setup is better suited to a defined-risk convexity trade than a cash equity chase.
• If FORM has already run meaningfully in the last month, wait for a 3-5% pullback before adding; estimate-revision names often get one more leg, but entries after air pockets have better risk/reward.
• Trim or hedge if the next consensus update is flat-to-down, because the stock’s near-term support is likely flow-driven and can reverse quickly once revisions stall.